Teva Pharmaceutical and Medincell announce FDA acceptance of NDA for olanzapine extended-release injectable suspension for the treatment of schizophrenia in adults ($33.92, -0.41)
U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Corcept comments on patent dispute with Teva Pharmaceuticals ($34.24, 0.00)
Appeals Court affirms district court ruling that Teva's proposed generic Korlym does not infringe Corcept Therapeutics' '214 and '800 patents -- court filing ($37.20, -2.62)
StreetAccount Sector Summary - Healthcare Pre-Market
StreetAccount Sector Summary - Healthcare Post-Market
Notable 13F filings in Healthcare (Q4 2025)
Greenlight (Einhorn) discloses material changes in holdings in 13F filing
StreetAccount Summary - US Pre-market trading update
Powered by FactSet Research Systems Inc.